HIV drug development: the next 25 years
Top Cited Papers
- 1 December 2007
- journal article
- review article
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 6 (12) , 959-966
- https://doi.org/10.1038/nrd2336
Abstract
HIV has been the most active field of antiviral drug research and development since the discovery of the virus a quarter of a century ago. Flexner provides an overview of current opportunities and novel targets in HIV drug discovery, and analyses the central questions pertinent for the next 25 years of drug development for HIV. The development of drugs for HIV infection began soon after the virus was discovered 25 years ago. Since then, progress has been substantial, but numerous uncertainties persist about the best way to manage this disease. Here we review the current treatment options, consider novel mechanisms that can be exploited for existing drug targets, and explore the potential of novel targets. With a view to the next quarter century, we consider whether drug resistance can be avoided, which drug classes will be favoured over others, which strategies are most likely to succeed, and the potential impact of pharmacogenomics and individualized therapy.Keywords
This publication has 35 references indexed in Scilit:
- Multiple-Dose Escalation Study of the Safety, Pharmacokinetics, and Biologic Activity of Oral AMD070, a Selective CXCR4 Receptor Inhibitor, in Human SubjectsAntimicrobial Agents and Chemotherapy, 2007
- The HBV Drug Entecavir — Effects on HIV-1 Replication and ResistanceNew England Journal of Medicine, 2007
- Class of Antiretroviral Drugs and the Risk of Myocardial InfarctionNew England Journal of Medicine, 2007
- Out of Africa: what can we learn from HIV-2 about protective immunity to HIV-1?Nature Immunology, 2007
- Reduced Maximal Inhibition in Phenotypic Susceptibility Assays Indicates that Viral Strains Resistant to the CCR5 Antagonist Maraviroc Utilize Inhibitor-Bound Receptor for EntryJournal of Virology, 2007
- Antiretroviral activity of pegylated interferon alfa-2a in patients co-infected with HIV/hepatitis C virusJournal of Antimicrobial Chemotherapy, 2007
- Drug Development Strategies for Salvage Therapy: Conflicts and SolutionsAIDS Research and Human Retroviruses, 2006
- A Prospective, Randomized Trial Examining the Efficacy and Safety of Clarithromycin in Combination with Ethambutol, Rifabutin, or Both for the Treatment of Disseminated Mycobacterium avium Complex Disease in Persons with Acquired Immunodeficiency SyndromeClinical Infectious Diseases, 2003
- Big physics, small doses: the use of AMS and PET in human microdosing of development drugsNature Reviews Drug Discovery, 2003
- A Randomized Trial of the Activity and Safety of Ro 24-7429 (Tat Antagonist) versus Nucleoside for Human Immunodeficiency Virus InfectionThe Journal of Infectious Diseases, 1995